| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Bacterial therapy for irritable bowel syndrome
|
Talley, Nicholas J
|
|
|
5 |
7 |
p. 627-629
|
article
|
| 2 |
British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis
|
Powell, Nick
|
|
|
5 |
7 |
p. 679-697
|
article
|
| 3 |
Converging pandemics: implications of COVID-19 for the viral hepatitis response in sub-Saharan Africa
|
Gupta, Neil
|
|
|
5 |
7 |
p. 634-636
|
article
|
| 4 |
Correction to Lancet Gastroenterol Hepatol 2020; 5: 425–27
|
|
|
|
5 |
7 |
p. e6
|
article
|
| 5 |
Correction to Lancet Gastroenterol Hepatol 2020; 5: 649–57
|
|
|
|
5 |
7 |
p. e6
|
article
|
| 6 |
Correction to Lancet Gastroenterol Hepatol 2020; 5: 667–68
|
|
|
|
5 |
7 |
p. e6
|
article
|
| 7 |
Could a kiwifruit a day keep the doctor away?
|
Dimidi, Eirini
|
|
|
5 |
7 |
p. 648
|
article
|
| 8 |
Determining risk factors for mortality in liver transplant patients with COVID-19
|
Webb, Gwilym J
|
|
|
5 |
7 |
p. 643-644
|
article
|
| 9 |
Drinking alone: COVID-19, lockdown, and alcohol-related harm
|
The Lancet Gastroenterology & Hepatology,
|
|
|
5 |
7 |
p. 625
|
article
|
| 10 |
Early detection of pancreatic cancer
|
Pereira, Stephen P
|
|
|
5 |
7 |
p. 698-710
|
article
|
| 11 |
Green endoscopy: a call for sustainability in the midst of COVID-19
|
Maurice, James B
|
|
|
5 |
7 |
p. 636-638
|
article
|
| 12 |
Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial
|
Andresen, Viola
|
|
|
5 |
7 |
p. 658-666
|
article
|
| 13 |
Implications of gastrointestinal manifestations of COVID-19
|
Yang, Lijing
|
|
|
5 |
7 |
p. 629-630
|
article
|
| 14 |
Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis
|
Mao, Ren
|
|
|
5 |
7 |
p. 667-678
|
article
|
| 15 |
Patterns of care for inflammatory bowel disease in China during the COVID-19 pandemic
|
Chen, Yan
|
|
|
5 |
7 |
p. 632-634
|
article
|
| 16 |
Prevention of COVID-19 in patients with IBD
|
Segal, Jonathan P
|
|
|
5 |
7 |
p. 639-640
|
article
|
| 17 |
Prevention of COVID-19 in patients with IBD – Authors' reply
|
Ding, Nik Sheng
|
|
|
5 |
7 |
p. 640-641
|
article
|
| 18 |
Probiotics and COVID-19: one size does not fit all
|
Mak, Joyce W Y
|
|
|
5 |
7 |
p. 644-645
|
article
|
| 19 |
Protecting patients with IBD during the COVID-19 pandemic
|
Fiorino, Gionata
|
|
|
5 |
7 |
p. 639
|
article
|
| 20 |
Research in brief
|
Baker, Holly
|
|
|
5 |
7 |
p. 647
|
article
|
| 21 |
Resumption of daily services in a gastroenterology department in Guangzhou, China, in the wake of COVID-19
|
Han, Jing
|
|
|
5 |
7 |
p. 645-646
|
article
|
| 22 |
Screening FMT donors during the COVID-19 pandemic: a protocol for stool SARS-CoV-2 viral quantification
|
Ng, Siew C
|
|
|
5 |
7 |
p. 642-643
|
article
|
| 23 |
Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study
|
Feld, Jordan J
|
|
|
5 |
7 |
p. 649-657
|
article
|
| 24 |
Shortening treatment with direct-acting antivirals in HCV-positive organ transplantation
|
Holmes, Jacinta A
|
|
|
5 |
7 |
p. 626-627
|
article
|
| 25 |
Views of patients with inflammatory bowel disease on the COVID-19 pandemic: a global survey
|
D'Amico, Ferdinando
|
|
|
5 |
7 |
p. 631-632
|
article
|
| 26 |
Wastewater monitoring of SARS-CoV-2: lessons from illicit drug policy
|
Lancaster, Kari
|
|
|
5 |
7 |
p. 641-642
|
article
|
Journal description